Crizotinib Restored Pembrolizumab Response in Advanced Non-Small Cell Lung Cancer
Laila C. Roisman(Shaare Zedek Medical Center)
Cited by 0
Related Papers
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
|Journal of Thoracic Oncology|2018|220